Generation of new RNA medicine candidates based on the chemically modified and IP-protected nucleotides.
BUSINESSWe design novel RNA medicines and synthesize various derivatives by using chemically modified nucleotides.
We have designed and synthesized several siRNA molecules which showed promising anti-Covid-19 and/or anti-cancer activities.
The primary business of GFM is the discovery and development of innovative RNA therapeutics in collaboration with Solstar Pharma in Canada and leading laboratories in the world to share the technology and intellectual property of nucleotide chemistry developed at Gifu University.
BUSINESSProviding our technology to pharmaceutical companies
We cooperate with pharmaceutical companies to find the most suitable formulation and drug delivery.
BUSINESSCollaboration with special research agencies and academia
GFM gladly accepts the contract research from university laboratories and pharmaceutical companies.